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Abstract
Background: The South African (SA) public health system has employed an Essential Medicines List (EML) with
Standard Treatment Guidelines (STGs) in the public sector since 1996. To date no studies have reported on the
process of selection of essential medicines for SA EMLs and how this may have changed over time. This study
reports on the decision making process for the selection of essential medicines for SA EMLs, over the years, as
described by various members of the National Essential Medicines List Committee (NEMLC) and their task teams.
Methods: Qualitative in-depth interviews, guided by an interview questionnaire, were conducted with 11 members
of the SA NEMLC and their task teams (both past and present members) during the period January – April 2015.
Interviews were recorded and transcribed verbatim. Transcripts were then coded by the first author and verified by the
second author before being reconciled and input into NVIVO, a qualitative software, to facilitate analysis of the data.
Results: The interviews conducted suggest that the NEMLC process of medicine selection has been refined over the
years. This together with the EML review process is now essentially predominantly an evidence based process where
quality, safety and efficacy of a medicine is considered first followed by cost considerations which includes
pharmacoeconomic evaluations, and pricing of medicines.
Conclusions: This is the first study in SA to report on how decisions are taken to include or exclude medicines on SA
national EMLs and provides insight into the SA EML medicine selection, review and monitoring processes over time.
The results show that the NEMLC has undergone tremendous transformation over the years. Whilst the membership
of the committee largely remains unchanged, the committee has developed its policies and processes over the years.
However there is still a need to strengthen the monitoring and evaluation aspects of the SA EML policy process.
Keywords: Essential medicines, Essential medicines lists, Selection of essential medicines, South Africa, Standard
treatment guidelines
Background
The healthcare landscape in South Africa (SA) has under-
gone considerable change since the instatement of the
country’s new democratic government in 1994 and the
subsequent adoption of the National Drug Policy (NDP)
for SA, published in 1996 [1]. The country has since been
engaging in healthcare reform to ensure equitable access to
healthcare and medicines for all citizens, especially those
previously disadvantaged by the racially fragmented and
under-resourced healthcare services created by the apart-
heid system [2]. The healthcare system in SA is still a two
tier system consisting of both public and private sectors of
healthcare. The public sector has three levels of care (PHC,
secondary hospital and tertiary/quaternary hospital). One
of the key goals of the NDP for SA, through the essential
drugs programme (EDP), was to establish a Ministerial
appointed National Essential Medicines List Committee
(NEMLC) who was responsible for the development of an
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essential medicines list (EML) for use in the public health-
care sector and to prepare standard treatment guidelines
(STG) for the health professionals [1]. This goal was
attained when the country’s first STG and EML was pub-
lished for Primary Healthcare (PHC) in 1996 [3].
Since then there have been 12 editions of the STG/EML
published for two levels of healthcare, viz. a PHC book
and separate books for adult and paediatric hospital level.
The tertiary/quaternary level EML is a list of recommen-
dations and non-recommendations of treatment for spe-
cific conditions. This is a constantly updated document
and is only available on the National Department of
Health (NDoH) website [4]. The SA EML is a list of medi-
cines derived from the STGs.
The NDP explains that one of the drivers for the de-
velopment of the SA EML was the deficiencies in the
pharmaceutical sector such as the rising costs and ir-
rational use of medicines [1]. The creation of an EML
was expected to lower the costs of medicines and im-
prove the rational use of medicines by ensuring a limited
number of medicines considered essential would be
listed and procured [1, 5]. The sector-wide procurement
division of the NDoH is responsible for selecting essen-
tial medicines, developing STG/EMLs, administration of
health tenders, and licensing of individuals and facilities
responsible for delivering pharmaceutical services [6]. In
a middle-income country setting like SA and in a time
of economic crisis and rising costs, there needs to be
controls in place to ensure efficient use of the resources
for medicines, whilst improving the rational use of medi-
cines, but without compromising the quality of healthcare
delivered. The World Health Organization’s (WHO) state-
ment on the advantages of having an EML based on the
judicious selection of medicines [7] supports this idea:
“The careful selection of a limited number of essential
medicines results in a higher quality of care for patients,
better management and use of medicines and more
cost-effective use of health resources. Clinical guidelines
and lists of essential medicines may improve the avail-
ability and proper use of medicines within health care
systems. Selection of medicines follows market approval
of a pharmaceutical product which defines the availabil-
ity of a medicine in a country. An essential medicines list
may then be developed based on disease prevalence,
evidence on efficacy and safety, and comparative
cost-effectiveness”.
Thus essential medicines are regarded as medicines
that satisfy the priority health care needs of the popula-
tion. The implementation process of the essential medi-
cines concept must ensure it is flexible and adaptable to
suit the needs of the country and selection of essential
medicines is a national obligation [8].
The process of selection of medicines in South Africa,
in line with STGs, is not easily available in the public
domain. Little is known about the NEMLC processes for
medicine selection and how these have changed over
time. There also seems to be a lack of published infor-
mation on suggestions and ways to improve the SA
EML policy implementation as it evolves over the years,
which could benefit other low and middle income coun-
tries. This study aimed to fill this gap in knowledge and
reported on the decision making process for the selec-
tion of essential medicines for SA STG/EMLs and man-
agement thereof, over the years, as described by various




Qualitative studies usually involve smaller samples as
compared to quantitative studies as qualitative studies
focus on meaning instead of making generalised hypoth-
esis. Large sample sizes are most often unnecessary for
qualitative analysis as a single occurrence of a piece of
data is sufficient to form part of the analysis framework
and one piece of data is as useful as many in creating an
understanding of the process behind a topic. A small
sample also ensures the researcher can form a more
meaningful bond and establish rapport with the partici-
pants for a richer discussion and interview process. Fur-
thermore, qualitative research can be labour intensive
for very large samples and are sometimes impractical
given the time constraints within which to complete the
research [9, 10]. Thus, in-depth interviews with 11 par-
ticipants, who were/are members of the South African
National Essential Medicines List Committee, were con-
ducted from January to April 2015. The sample was se-
lected from the full list of members of the NEMLC (104
members) and Technical Expert Review Committees
(TERC) (71 members) extracted from each edition of
the 10 EMLs published from 1996 to 2012. Participants
were then purposively selected based on the number of
times they had served on each of the committees as well
as the number of levels they served on. This was done to
ensure inclusion of all types of members (representatives
from all 9 provinces in the country, both previous and
new members; members who served on one or both
committees, members who served for one or more years;
members who served on one or more level of healthcare
EML). Invitations to participate in the study were sent
to 20 members, of which 11 responded and agreed to
participate in the study. Although representation from
all 9 provinces in SA was not achieved in the sample,
data saturation was achieved with the existing number
of participants.
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Development of the instrument
The interview guide for this study was based on the
American Society of Health-system Pharmacists formulary
questionnaire for formulary management and adapted for
the public sector NEMLC in SA [11]. The first draft of the
interview guide for the in depth interviews with NEMLC
members was piloted with a current member of the
NEMLC known to a member of the research team. The
interview tool was subsequently refined based on the rec-
ommendations made during this pilot interview. The
interview tool included open ended questions about com-
mittee composition, roles and responsibilities; national
policies regarding the committee’s process of selection of
medicines and how the committee maintains the list and
monitors the rational use of essential medicines.
Data collection
The interviews were carried out from January to April
2015 and were conducted by the researcher who had no
previous knowledge of the workings of the NEMLC and
EMLs. There was therefore no prejudgement regarding
likely answers to the questions. The researcher was able
to limit probing of issues that emerged during the inter-
view thereby eliminating bias and possible influence by
the researcher. All except one of the interviews were
audio recorded after obtaining consent from the partici-
pants. In the case where consent was not granted, de-
tailed written notes were taken.
A review of the NEMLC policy documents available
on the NDoH website was also undertaken. This was
done to increase understanding of the processes as re-
ported in these documents, to validate responses from
the participants during the in-depth interviews and to
further verify information obtained from the literature.
Data processing and analysis
All interviews were conducted in English as all re-
searchers and participants were fluent in the language.
The recorded interviews were transcribed verbatim. One
recording was inaudible and subsequently excluded from
the study. Transcripts were then coded by the first
author and verified by the second author. Discussions
were held to clarify any discrepancies in coding and to
reach consensus. These transcripts and codes were then
reconciled and entered into NVIVO, which is qualitative
software, to facilitate analysis of the data. A thematic
analysis approach was used based on grounded theory
where data was coded into hierarchies after an iterative
process of classifying codes and re-classifying into sub-
codes to ensure no new themes emerged.
Ethics statement
The study was granted ethical clearance by the University
of KwaZulu-Natal Human and Social Sciences Research
Ethics Committee (HSS/0154/013). Consent to conduct
the interviews with members of the NEMLC was also ob-
tained from the Sector-wide procurement cluster manager
at the SA National Department of Health.
For ease of reference and to provide context to the
comments from participants, the authors have included
the period of service of participants on the NEMLC in
brackets after a quote.
Results
Response rates and description of sample
Only 11 out of the 20 members (previous and current)
originally invited to participate, responded and agreed to
participate in the study, namely four from the NDoH in-
cluding one previously part of the secretariat; five from
academic institutions; one from a provincial Pharmacy
and Therapeutics Committee (PTC); and one from a pro-
vincial Department of Health (DoH). This sample was
representative of four of the nine provinces in South
Africa namely Gauteng, KwaZulu-Natal, Eastern Cape
and Western Cape. These are the four most densely popu-
lated provinces (23.7, 19.8, 12.7, 11.2%) [12]. Provinces
that were not represented include Free State, Limpopo,
Mpumalanga, Northern Cape and North West. Three par-
ticipants have also Chaired the committees at different
times during their term/s of service. The level of involve-
ment of sample participants with the NEMLC and TERC
ranges from one term of service for one level to multiple
terms of service for one or more levels. Thus, the sample
is representative of new and older, longer serving mem-
bers and is inclusive for all 3 STG/EMLs (PHC, Adult and
Paediatric). It is also important to note that there is over-
lap in service on the committees as some participants
have served on both the NEMLC and TERC at different
times during their terms. The age range of participants
was 37–62 years. Table 1 shows the demographic charac-
teristics of the study sample.
The key themes derived from the interviews were: 1.
The NEMLC; 2. Medicine selection for the STG/EML; 3.
Implementation, monitoring and evaluation of STG/
EML; and 4. Change over time. These will be presented
separately in the sections to follow.
1. The NEMLC
This section encompasses the sub-themes that describe
the composition of the committee, how these members
are selected, what their roles and responsibilities are, and
how the committee develops and manages its policies.
1.1. Membership, selection of members and conflict
of interest declarations
When asked to describe the membership of the com-
mittee most participants were able to describe in general
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the type of people selected for the committee. One par-
ticipant responded in detail
“there are content experts, technical experts; there are
provincial representatives that are nominated by the
head of health or of the province. Each province has a
seat around the table. We have representation from
the programme within the department of health and
of course then we do have, as I said, the normal
technical experts. So the chairs of the expert review
committee who submits recommendations to the
national essential medicines list committee are also
part of the EML committee” (Secretariat),
When asked to describe the process of selection of
members onto the committee most participants had a
very general idea and one participant was unsure. One
participant responded:
“Members are selected from pharmacists and medical
professionals around the country. Generally, these
people would’ve been people active in the provincial
PTCs but not always. There’s a wide spectrum of
people. Committees are appointed by invitation from
the Minister and there is a call for nominations that
goes out to most government departments. And it’s
upon answering a call for nominations like this that
one is invited to participate in the committee. So,
there are pharmacists and various medical specialists
and public health people and then there are also
people from the directorates, and TB directorates,
that sort of thing” (2013).
The following flow diagram (Fig. 1) of the process of
selection of members for the NEMLC was developed
from the information provided by the participants and a
notice of call for nomination form [13].
When the topic of conflict of interest in the member-
ship of the committee was addressed all participants
were knowledgeable regarding said criteria. It was appar-
ent from the interviews that a conflict of interest guid-
ance document is made available to committee members
at the very first meeting and a declaration must be
signed before being appointed. Thereafter a conflict of




Average age 49 years
Age Range 37–62 years




3 - Western Cape
1 - Gauteng
3 - KwaZulu-Natal (one from the Provincial PTC)
1 - Eastern Cape (provincial DoH)
3 - National Department of Health (1 Secretariat)
Fig. 1 Selection of members for the NEMLC
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interest declaration is signed at every meeting to ensure
that there is no conflict for that particular meeting as
conflict may arise for one meeting but not for another.
Responses of participants’ were as follows:
“As an example where now we have a haematologist
that’s appointed and he’s a member of the haematology
society. So when we discuss blood and blood forming
organs chapter, we discuss inhibitors for example,
we have to consider his conflict of interest when
decisions are made. We might have to, for example,
exclude him from discussion if it’s very conflicted or if
it’s a minor conflict he can be part of it but not part of
the decision making. We have to take it on by a case by
case basis” (2012).
“There is a potential conflicts of interest policy or a
guidance document which is also available on the
department of health website… The chairperson decides
how the conflict of interest impacts on the discussions at
the meeting. So we rely on members to declare honestly
what their conflicts of interests are, we don’t go and
investigate their conflicts of interest so it depends on
how ethical the members are themselves.” (Secretariat).
1.2. Roles and responsibilities of the committee
members
The description of the roles and responsibilities of the
various members of the committee was compiled from
participants’ responses when asked to define their pos-
ition and role on the NEMLC as follows:
 Chairperson – presides over and conducts the
meetings, manage conflict of interest situations and
to facilitate discussion.
 Secretariat – forms part of the supporting structures
to the NEMLC both administratively and technically.
In terms of administrative roles they facilitate the
flow of documentation between committees and
committee members, facilitate the logistics and
travel arrangements for meetings, printing and
editing of documentation. They facilitate all
communication to and from the committee and the
department to external and internal stakeholders.
Their technical role is to assist committee members
with recording their decisions and to assist with
reviews that are undertaken. They also ensure that the
committee members abide by the department of
health policies and guidelines.
“The secretariats sit on the PTC. Decisions that are
made there are minuted. And the idea is that these
decisions are fed back to the provinces by the
secretariat to the heads of the pharmacy services of
the provinces. And the expectation is that those heads
then communicate with their local provincial PTCs
(PPTCs). And those provincial PTCs speak to the
hospital PTCs, regional PTCs” (2013).
“Secretariat is represented at each of these and at
national level. And that allows for some smooth flow
and continuity and also it keeps the thread going as
the members go back to their respective
constituencies to do their work before each of the
meetings takes place”(1998–2012).
 Technical experts – expert review committee
“To provide technical input as part of the review
process, to provide recommendations to the
NEMLC”(2012).
 Provincial representatives –
“role is to provide feedback from provincial side of
changes that have been made. If ratified, any new
items in the province that are non-essential meds and
also to provide the review, usually called a one-page
review” (2013).
1.3. The development of NEMLC policies and its
management
Until recently the NEMLC policy documents on mem-
bership, conflicts of interest, and terms of reference have
not been made available in the public domain. A review
of these NEMLC policy documents was undertaken as a
triangulation to the in-depth interviews and information
found in the literature. There were no reports of in-
depth interviews with SA NEMLC members and infor-
mation on the SA EDP and its processes was limited in
the literature. Thus, the cross verification from these dif-
ferent sources helped capture different perspectives of
the NEMLC policies and also served to validate this
study. The following are summaries of the NEMLC pol-
icy documents currently available on the NEMLC page
on the NDoH website [14]:
a) Declaration of Interests: states that each NEMLC
member must review the NEMLC’s guidance
document on declaration of interest prior to
undertaking this declaration to ensure the selection
of medicines for the STG/EML is done in an
independent atmosphere which is free of direct or
indirect pressures.
b) Confidentiality guidance document: This document
guides NEMLC members, members of the expert
review committees and any working groups
established by the committee as to the
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circumstances in which they should maintain
confidentiality regarding the decisions of the
committee and its source documents.
c) Declaration of Interests Guidance Document:
Guides NEMLC members, members of Expert
Review Committees and any working groups
established by the committee as to the
circumstances in which they should declare an
interest in the health care industry.
d) Terms of reference (February 2013): details the
purpose of the NEMLC, their authority to act,
composition, conditions of membership, termination
of membership, code of conduct, the roles of the
Chairperson; secretariat; and various categories of
members (technical experts, provincial representatives,
major clinical programmes representatives), meeting
procedures of the NEMLC, medicine technical report,
expert review committees of the NEMLC, general
procedure for review of an EML publication, meetings
and communications with stakeholders.
e) Notice of call for application to the NEMLC
(11th October 2016): detailing eligibility criteria
for applicants for the position.
An assessment of changes in these policies over the
years is difficult to make as these documents, with the
exception of the terms of reference and the notice of call
for nomination, are not dated. Thus it is difficult to de-
termine when these documents were drawn up, revised
or published. Also, there is no repository or archives of
previous versions of policy documents if in the event
they were revised. The assessment of changes in these
policies is therefore extrapolated from the responses of
the interview participants.
When asked if the NEMLC consulted other stake-
holders to develop its management plans and policies,
most participants indicated that there was some consult-
ation although this may not be particularly pertinent to
their management policies.
“…We do consult with people. For example, the
antimicrobial resistance strategy that was circulated
for comment as part of one of the policies we
developed to curb antimicrobial resistance and was
launched by the Minister after all the stakeholders
had been consulted. We do that. Going forward that
would be the way we develop policies”. (Secretariat)
“So the cluster management for TB and HIV, they’d
be consulted and they’d be shown fresh diseases and
sometimes chronic diseases. There should be some
sort of collaboration just to keep people informed. I
don’t think we’ll ask them to develop policies for us”
(2003–2012).
And to the contrary, one member said
“No. Thus far I haven’t seen any consultations
happening” (PTC member, 2013).
This was probably due to the short term of service as
this was a new member on the committee at the time
the interview was conducted.
When addressing the question, When are NEMLC
policies reviewed and revised? most participants inter-
preted this question to be pertinent to the STG/EML it-
self and responded that it was reviewed on a 2–3 year
cycle. Many did not consider the policies surrounding
the confidentiality declaration, conflict of interest or the
Terms of Reference of the committee in particular and
did not comment on these. The responses were varied
for those that did provide comment:
One participant was unable to provide a timeframe
for review of policies, one said it was “sporadic”
(1998–2012) and another said that
“the revision of the Terms of Reference may fall
under the entire NEML process and may be
lacking” (2003–2012)
Two participants’ responses concurred that NEMLC
policies were reviewed on a 3 year cycle upon appoint-
ment of a new committee:
“the committee is appointed on a three year cycle so
the terms of reference and all the SOP’s and policies
are reviewed in the same cycle. And as we progress
with the review, if we encounter an issue which
requires an amendment to the policy, it is changed
in accordance with the changing environment”
(1996–2012).
“Okay it’s not very often because it depends on the
environment, if there is something in the policy that
needs to be reviewed then we do it on an adhoc basis.
The national essential medicines list committee policies
are reviewed on the appointment of that committee
which is after every three years” (Secretariat)
2. The selection of medicines for the STG/EML
The process of medicine selection is now encom-
passed in the review process of the STG/EMLs since
the process entails updating the original document
produced in 1996. The entire process of decision
making for the addition or deletion of medicines on
the STG/EML hinges on the following sub-themes:
the decision flow system; consultations for decision
making; and stipulated criteria for medicine selection.
These are described in this section together with
Perumal-Pillay and Suleman BMC Health Services Research  (2017) 17:17 Page 6 of 17
other factors influencing the process of medicine
selection.
2.1 Decision making and the decision flow system
The NEMLC is the decision making body. Their support
structures include the 4 subcommittees, the PTCs and the
Secretariat. The 4 subcommittees are the technical expert
review committees for the PHC, Adult Hospital level,
Paediatric Hospital level, and Tertiary/Quaternary level.
These subcommittees do the groundwork (literature re-
view, critical appraisal of evidence) for the review of the
chapters for the STG/EMLs for those levels and make rec-
ommendations to the NEMLC. The subcommittee re-
ceives input from the various stakeholders (provincial and
institutional PTCs, clinical societies, universities). Repre-
sentatives from the PTCs are also members of the sub-
committees who provide input at ground level from the
various hospitals. The secretariat is responsible for the ad-
ministration and facilitates communication between sub-
committees and the national committee. It is also
worthwhile to note that the chair of each of the 4 subcom-
mittees also sits on the NEMLC, so these individuals are
involved in the review process at subcommittee level as
well as in the decision making process at national level.
This may be seen as linking the separate committees for
easing the decision-making and review processes. Final
decisions on medicines selection are made by the NEMLC
and presented to the Minister of Health for endorsement.
Most participants were aware of the decision flow system
between structures and were able to provide detailed ac-
counts of their understanding of the flow of information.
The following schematic of the decision flow system
(Fig. 2) was developed from the information provided by
the participants.
Fig. 2 The decision flow system for the decision making process for STG/EML review and the inherent medicine selection process
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2.2. Consultation for decision making
When consultation with other committees for the pur-
pose of decision making for medicine selection was dis-
cussed, participants responded that consultations may
not have happened in the very first committee when the
EML was being developed but did occur in later years
during the EML review process:
“I don’t recall that we had that mechanism in place
at the beginning, it might have been developed
later”. (1996)
“The way the constitution of the committee is
established is that there is a multi-disciplinary and
multi-stakeholder contribution towards the decision
making.” (1996–2012).
“there’s wide consultation with all the provinces and
with the health science faculties. And we also try and
circulate chapters, both draft, both when we starting
out with a new process and when we’ve got the final
draft we also will include societies, hypertension
societies, HIV clinician societies, those kind of
societies.” (2003–2012).
2.3 Criteria for medicine selection and evidence
based medicine
The general consensus from participants of the
process of medicine selection, and in particular the
process of adding or deleting medicines, is that this
process is inherent in the EML review process as repre-
sented in the schematic in Fig. 2. This process is
followed unless there is a specific reason to reconsider
the listing of a medicine such as a medicine safety alert
such as detrimental side effects, in which case this is ad-
dressed at the next NEMLC meetings which are sched-
uled regularly. There is a meeting once a week for
certain committees. The participants’ responses indicate
that the process of medicine selection has always been
an evidence based process since the very first EML in
1996. The criteria for selection and use of evidence
based medicine over the years have become more robust
and stringent. When participants were asked if decisions
for medicine selection were evidence based the answer
was always “yes”. However, many commented on the
limitation being the quality of evidence available to sup-
port the decision making process.
“If there’s going to be a change in the guideline, a
drug being deleted or a drug being added, then all of
the evidence needs to be reviewed”(2003–2012).
One participant provided a detailed account of the
process of adding a medicine, which is explained below:
“…well the decisions are made based on, using
evidence based medicine principles. Whenever a
medicine is added, the question is asked whether or
not there’s a medicine that needs to be deleted…they
are instructed to look at various things. ABC analysis
at a national level, they need to look at tenders, they
need to look at pricing, trends internationally, they
need to look at departmental guidelines, society
guidelines, international guidelines. Also, they are
appointed because they have an expertise in a certain
area so they should know where the evidence is
moving. They then compile the amended changes to
the Standard Treatment Guidelines. So, our process is a
Standard Treatment Guidelines derived one. If they
arrive at a point where they feel that there’s a necessity
to add a new medicine then there’s a medicine technical
report. That report and the amended Standard
Treatment Guidelines are then peer reviewed by the
technical subcommittee. The technical subcommittee
either sends it back to the reviewer to address or it is
finalised in the meeting. Then it goes to National
Essentials Medicine List committee. They then
approve it for distribution and it is distributed, as I
said, to universities, provincial structures,
institutional structures as well as clinical societies.
Comments are then received within the comment
period. Those comments then are reviewed.
Hopefully they are supported by evidence. If there
is no evidence, we will make a judgement call as to
whether or not we will look up the evidence. We
will then amend the chapter accordingly. Then it
goes to National Essential Medicine List committee
and if they endorse it, then it goes for editorial
process and that chapter is finalised” (1996–2012).
The most popular reasons provided for deleting medi-
cines were safety concerns, high cost, poor availability; a
new medicine becomes available or genericized to re-
place an existing one.
The principles or criteria for medicine selection as ex-
plained by the participants are safety, efficacy, quality,
cost-effectiveness, health economic analysis, pharmaco-
economic analysis, ABC analysis, Quality Adjusted Life-
Years, tenders, therapeutic classes, and cost.
“…we have principles of how we select medicines, we
base it on equity, evidence based decision making, we
look at the needs, priority of health clinicians, safety,
efficacy, equality, we look at affordability and also
actual implications of introducing the medicine to the
practice environment”(2012).
From the participants’ responses it is evident that the
principles of Evidence Based Medicine (EBM) are deeply
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entrenched in the NEMLC medicine selection process
and no decision is ratified unless the evidence has been
considered. The NEMLC employs the Strength of Recom-
mendation Taxonomy (SORT) criteria for the grading of
evidence in the medical literature and uses the Appraisal
of Guidelines for Research and Evaluation II (Agree II In-
strument) for assessing and developing standard treatment
guidelines from which the EML is extracted.
The SORT taxonomy is a grading scale which allows
the application of one taxonomy to many sources of evi-
dence. It speaks to the quality, quantity and consistency
of evidence for the assessment of individual studies or
bodies of evidence. The framework for this taxonomy fo-
cuses on the use of patient-oriented outcomes that
measure changes in morbidity or mortality [14].
The AGREE II instrument is used to assess the
methodological rigour and transparency in the devel-
opment of a clinical practice guideline. It provides a
framework for the assessment of the quality of exist-
ing guidelines; provides a methodological strategy for
developing guidelines; and advises on the type of in-
formation required and how this should be reported
in the guidelines [15].
Members recounted how EBM principles are applied
in the EML process as follows:
“So we have a reviewer guideline that gives guidance
on how, what kind of information to look at. The
committee member who is doing the review is
generally the person that will source the information
based on the search strategy. You know the whole
PICO thing. So we follow evidence based medicine
principles. Then we try to impart that to our
committee members. Where they are unable to get
the articles the secretariat will get it for them. The
criteria is evidence based medicines criteria so you
have to look at your population and what is the
intervention, what is the outcome, what is the
comparators etc. Okay, the EML EDP programmes
use evidence based medicine principles, even for us
as policy makers we use evidence based decision
making. Obviously we will look at systematic reviews
with high quality randomised control trials as being
level 1 evidence, in the absence of that we look at
large studies with a properly conducted randomised
control trial. Then our quality of the evidence
decreases as we go along. If we don’t have any
systematic reviews of good quality trials, then we will
look at the single trial, you know single randomised
control trial. In the absence of that, then only we
look down the chain for other evidence. So then we
would look at observational studies or case control
studies in the absence of a randomised control trial
or a systematic review. Clinical trials are evaluated
and critiqued so we do that also as part of the
reviewer handbook” (Secretariat)
2.4 Other factors affecting the selection of
medicines
A number of other factors impacting on the decision
making process for medicine selection emerged from the
interviews. These include the roles of: (a) information
from pharmaceutical manufacturers, (b) therapeutic
classes of medicines, (c) tenders and cost considerations.
These are discussed below.
When asked about the use of information provided by
manufacturers in the selection of medicines, all participants
agreed that information from pharmaceutical companies is
not influential in decision making. Some have indicated that
although this information may filter through to the com-
mittee via a member it is not used in the decision making.
Dossiers from pharmaceutical companies are not consid-
ered and are viewed as bias. Participants’ responses include:
“…in my experience the committee views published
pharma-economic analyses, especially with heavy in-
fluence from the manufacturers, with a great degree
of scepticism” (2013).
“We’ve had a few comments from outside experts
where we strongly suspect that the pharmaceutical
companies are behind them but we don’t use that
dossier. We look for our own evidence, so we never
use the manufacturer’s dossier because it’s never
formally presented to the committee” (2003–2012).
On careful examination of the STG/EMLs over the
years, one will note the listing of therapeutic classes of
medicines instead of the listing of a particular medicine
as a treatment. This is related to the tendering and pro-
curement processes. Sometimes, this tendering process
impacts on the medicine selection process and medi-
cines may be selected because they fall within a particu-
lar therapeutic class as explained by one participant:
“they may say a therapeutic class, so they will say for
macrolides, let’s go with Azithromycin, Clarithromycin,
…then they’ll say let’s advertise it as a therapeutic class
for the sake of the tenders. So if the tender comes in
cheaper for one macrolide over the other, one will be
chosen and the other will be removed. So that’s why
they are now citing examples in the EML” (2013).
“….so we compare prices on the tender price, so then we
can select the most affordable medicines” (20013–2012).
Health economic considerations also play an import-
ant role and participants have indicated that cost is not
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the driving factor in the medicine selection process. Many
have indicated that some kind of pharmaco-economic
analysis is performed during the selection process but the
general consensus is that it is currently not a very compre-
hensive process and could be improved upon.
“….it’s not just the cost of the medicines but we try
and express costs in terms of changes in quality
adjusted life years. It’s not always that easy but we do
a rough estimation we don’t do a formal health
economic analysis, it would just take forever if we did
that. But we are very mindful of costs and we are not
taking the attitude that if it’s expensive we can’t have
it. We look very carefully at the efficacy of the
medicine. And then also there are different people
within the Department of Health whose job it is to
negotiate with companies. So if we feel that a
particularly costly item is important, it’s kind of their
function to negotiate a better price and not the
NEMLC function. But clearly in a public health
system like ours, cost is a big factor” (2003–2012).
3. Implementation, monitoring and evaluation of
EML policy
The monitoring and evaluation (M&E) component of
an EML policy is vital for the successful functioning of
an EDP. This aspect provides information to policy
makers on how the policy and documents are being re-
ceived and accepted by those who need to implement it.
It further provides valuable information on which parts
of a policy are working and which are not, critical for
policy review and reform. The results of this study show
that this component is severely lacking in SA STG/EML
programme. Participants were asked a few questions to
ascertain the degree to which M&E took place, viz. Are
dates established to reassess the effect of an STG/EML
decision on the quality or cost of care? And how much
later after inclusion of a medicine on the STG/EML is
this assessed? Are outcomes monitored? Are there any
reports on monitoring the use of medicines by patients?
Responses suggested that no formal assessment was
done to evaluate decisions taken, no patient outcomes
were monitored by the NEMLC but rather they
depended on information from the PTCs who were re-
sponsible for this type of monitoring, and monitoring of
medication use.
“There’s no real assessment on the effect of a decision
on the quality or cost of care… Not a formal process”
(2003–2012).
“So the monitoring and evaluation of STG/EML is
problematic. DURs (Drug Utilization Reviews), that’s a
major problem, that’s a flaw. So we do ABC analyses
and all that, but there’s a flaw, we don’t really know if
it’s been used properly and what the DUR has done.
So it’s a major issue, DUEs (Drug Utilization
Evaluations) is not done at this moment in time. And
that certainly needs attention” (2003–2012).
Other challenges or shortfalls affecting the STG/EML
implementation, monitoring and evaluation processes
identified by participants include: (a) communication pro-
cesses between structures (national to provincial and de-
partmental) and the dissemination of information along
these lines; (b) the lack of health economic expertise in
the country; (c) the lack of country specific health eco-
nomic information impacting on health economic ana-
lyses; (d) poor outcomes monitoring and evaluation of
STG/EML decisions and rational use of medicines by pa-
tients; (e) blurred lines of roles and responsibilities be-
tween committees (PTCs, PPTCs, NEMLC); (f) alignment
of processes (medicines selection with procurement) in
the STG/EML process; and (g) challenges with availability
of appropriate paediatric medicines. Table 2 describes the
opinions of participants in relation to these challenges.
Further to the questions of our interview guide, one of
the participants posed extremely valuable questions
which addressed the future of the EMP. This was a step
further than the aims and scope of this study, but is well
worth mentioning as it is vital to the EMP and STG/
EML process in its entirety. The authors strongly recom-
mend and will investigate these questions as future stud-
ies as it impacts greatly on the strengthening and
sustainability of the overall STG/EML process. The par-
ticipant’s concerns are as follows:
“…is the process itself cost effective, or is there
funding around it?”
“Is there not a review committee there itself,… why
are consultants, typically experts, doing the review?”
“You may want to know why manufacturers don’t give
dossiers… why we don’t use the medical aid dossiers,
or why we don’t use data which has been looked at
already by, for example, the funding industry and the
private funding industry”
“…what is the succession planning, is there training,
do you train people to review?”
These are extremely important questions that if ad-
equately addressed could have huge consequences on
the cost of running the EMP and its overall impact in
terms of (a) developing guidelines for the use of infor-
mation from the private sector as well as some credible
information from the manufacturers; (b) improving
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Table 2 Participants’ opinions on challenges/shortfalls in the NEMLC and their processes
Issue Comment
Communication processes “I think one of the weaknesses in the committee is communication. They do communicate to the provincial people
but the provincial people then don’t always circulate it around. It is sent to all health sciences faculties but then
maybe it just dies in the Dean’s office and doesn’t get sent around. When people give comment, feedback is seldom
given to the individual commentators. Actually you know you can’t expect the secretariat to do everything. But the
committees recognise that communication back to people on the ground is an issue. Our main message of
communication in a way is the book, especially the primary care book. There’s a road show to provinces where new
changes are highlighted and explained and then the book is launched. There’s a team from DoH that goes down to
each province to explain that. So they try hard but it’s always hard to get down to the hundreds of thousands of
health care workers on the ground but that’s the process”. (2003–2012)
“The way of disseminating information is cumbersome and essentially goes to depots and pharmacists rather than
directly targeting prescribers, which is a problem”. (1998–2012)
“This has been one of the biggest challenges, I think. The movement of information from the EML committee to the
end users is something we’re working hard on. It’s an extremely difficult task because there’s so many role players
involved. There have been problems and complaints from provinces that the decisions are taken and no insight into
why certain decisions are being made. There’s very little opportunity for feedback and when there’s feedback given
there’s very little feedback on the feedback. So, the committee have taken up publishing rationales for every decision.
Those are available on the website, and can be circulated to people with queries, explaining what the rationale was
for a particular decision, reviewing the evidence base, doing the cost analysis, etc.” (2013)
“The communications between clinical advisors and pharmacist is robust”. (1998–2012) (exception)
Health economic expertise “So there is a lack of health economic expertise in the country. And within the committees there are people with
extra training in health economics and with good insight into it. But we do not do formal health economic analyses
on anything. We don’t have the time or the personnel to do that. But as I said earlier, we don’t just look at cost; we
try and express cost per quality adjusted life year. We use the rough world bank, WHO figure. That one to three
times per capita GDP per QALY is something to be considered. More than three is too much, under one is good. But
it’s not formal. It’s more a rough estimation to see whether we’re in the ball park rather than a formal process. It
would be great if we had the resources of NICE but we don’t. But we do aspire to it. So there are only a handful of
people with skill in the country. The EML keeps them all busy all the time and the EML has no budget for this. So we
see it as crucial but lack the expertise”. (2003–2012)
Lack of Health economic
information
“All of those were considered if the information was available. So anyone of those, whatever information, because
there often isn’t information on this particular subject although it’s considered important, in my latter days it’s
considered even more important as these disciplines were becoming more evolved. But there was always insufficient
information, but all of the criteria that you considered; they are all methods that were used if the information was
available”. (1998–2012)
“The answer is no because first of all there are many pricing considerations in the public sector which are not
relevant to international environments. So international cost effectiveness, or shall we say pharmaco-economic studies are
very rarely directly applicable to the South African environment. Again in the South African literature there have not been
many publications of pharmaco-economic evaluations as they pertain to the public sector”. (1996–2012)
“So one of the problems is that these types of studies are very rarely available. The pricing committee put out
guidelines for conducting pharmaco-economic studies. So the government have tried to facilitate the publication
thereof. So although I said no we don’t use them, we would love to use pharmaco-economic evaluations that are
appropriately targeted to the South African environment if they were readily available to us. We do look at international
studies but usually the international pharmaco-economic evaluations we use as a basis for constructing our own, so that




“So I think what I would say is, we aspire to that however the capacity in the country at the moment does not
support that but basically we have fantastic pharmaco-vigilance policies, as you know KZN has won partner, spent
millions of Rands on pharmaco-economic incentives and those sort of things” (1996–2012).
“At the moment people will give you answers as we think about it, but the reality is that the fantasy is not met. And
also remember at the national level we would be reliant on provincial competencies then and that’s going to be very
difficult. And one of the things that I lament all the time is, if you are sitting in graduation at the universities and you look
into all the funny thesis that people do, you wonder whether or not they’ll fit in South Africa because there’s very little,
ever, in academia or in our provinces where anyone ever looks at outcomes. So basically we are very reliant
on international publications. Obviously if you get a local publication we get very excited but they are very
very rare”. (1996–2012)
“The only internal data that we have readily access to, again because we haven’t been collecting it, because it’s not a
South African tradition to do so, is the information on the drug utilization, essentially. We basically have dispensing
data, which is becoming more detailed and of higher quality but that really addresses issues of affordability more than
anything else. And some questions of equity when you find a medicine is being used in one area and not being used in
another”. (1998–2012)
“The only mechanisms I recall at the time was to ensure that all prescribers had copies of the EDL and although this
was not done within government itself you had NGO’s running courses in drug supply management including
prescribing and dispensing. I think a lot more could have been done internally. I think this was a weak point on the
part of the government at the time we established the EDL”. (1996)
“So the monitoring and evaluation of EMLs is problematic. DURs, that’s a major problem, that’s a flaw. So we do ABC
analyses and all that, but there’s a flaw, we don’t really know if it’s been used properly and what the DUR has done.
So it’s a major issue. DURs is not done at this moment in time. And that certainly needs attention”. (2003–2012)
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human resources for the STG/EML review process in
terms of providing adequate training on the EBM princi-
ples and the review process itself and (c) ensuring sus-
tainability of the EMP by improving succession planning
initiatives in terms of providing opportunities for cap-
acity development of health professionals for these roles.
Some recommendations made by the Lancet Commis-
sions (2016) [16] on making medicines more affordable
by way of using Health Technology Assessment may
prove useful for the monitoring and evaluation compo-
nent of the EML policy and decision making process for
medicine selection in SA. The Health Technology As-
sessment method assesses the value of a new medicine.
It is a multidisciplinary mechanism that examines the
safety, clinical efficacy, effectiveness, cost, cost effective-
ness, organisational implications, social impacts, ethical
and legal consequences of the application of a drug or
other health technology. Health Technology Assessment
is a method that generates evidence to support procure-
ment and reimbursement for essential medicines selection
and can be used in price negotiations. Middle income
countries that have implemented Health Technology As-
sessment include Poland, Malaysia, and Colombia. SA can
learn from these countries experiences and adapt to our
setting. This would prevent double work, especially for
new expensive medicines.
4. Change over time
From the interview data an overarching theme de-
scribing the change over time emerged. This is described
in Table 3. which illustrates the progress made over the
years for both the NEMLC and its processes in terms of
(a) the improvement in time to review the STG/EMLs;
(b) more stringent criteria for medicines selection; and
(c) development of committee policies and processes to
more clearly address and define membership, conflicts
of interest, roles and responsibilities.
Discussion
In summary, the results from the interviews show that
the NEMLC has undergone tremendous transformation
over the years. Although the membership of the com-
mittee largely remains unchanged, the committee has
developed and improved its policies and processes over
the years. The selection of NEMLC members, their roles
and responsibilities are now more clearly defined in pol-
icy documents. Conflicts of interest are dealt with in a
formal manner with mandatory declarations by members
upon appointment and at each meeting. These docu-
ments have also recently been made available on the
NDoH website. This makes the processes more transpar-
ent as the information is now available in the public do-
main which was not the case previously.
The process of medicine selection has transformed
into an extremely rigorous evidence based process. The
process of medicine selection and process of review of
the STG/EML are underpinned by evidence based deci-
sion making. The time to review STG/EMLs has im-
proved over the years and the process is now almost a
continuous one with reviews of chapters occurring as an
ongoing process.
However, much attention and improvement is required
for the monitoring and evaluation component of the
EML process. There are also recommendations to ad-
dress the issues of sustainability of the NEMLC in terms
Table 2 Participants’ opinions on challenges/shortfalls in the NEMLC and their processes (Continued)
“It is a process I have criticised internally and externally as being short on review of its impact and whinge on process,
they keep on doing the same thing again and again but I think people are starting to accept that we may need to look
a bit harder at impact rather than just development”. (1998–2012)
Roles and responsibilities of
Committees
“I think there’s quite often confusion between the delineation of the National Essentials Medicine List committee
and that of pharmaceutical services….generally there’s confusion about the role and responsibilities of the two”.
(1996–2012)
Aligning processes – selection
and procurement
“It became clear that there has not been much interaction between the process of selection and that of procurement.
Quite often they will decide to select a medicine based on efficacy and even cost without looking at how widely
available it is. We have dozens of patients on treatment, failing the course, yet the medicines are supposed to be
good but it’s not readily available. And when you start putting patients on the medicine, then you have shortages
and patients lapse and so on. I would say that even up to a few years ago, there has not been a strong link between
selection and procurement”. (1996)
“I don’t know if it’s called a policy but they do have a SOP in place now to address medicine product shortages. They
have a formulary against which you check to see if the product is on tender etc. but the whole process is unclear. It’s
not like a policy; it was just like a circular that was sent around. There is a problem at present with transition in tender
and there are currently huge medicine shortages”. (PTC, 2013)
Challenges with paediatrics “One thing is, being a paediatrician and knowing that it’s a particularly difficult issue with paediatric drugs passed…
they are a particularly vulnerable group of patients. My personal opinion is that paediatrics needs its own Standard
Treatment Guideline process because it’s very different. Children should be prioritised not adults, according to the
constitution. So I think those two are important aspects. I think the committee focuses on a lot of adult guidelines
that isn’t the same and demands huge evidence burdens which isn’t available for children and which might result in
lack of availability for children”. (2013)
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of its succession planning, capacity building, and men-
toring and training in EBM principles and review of the
STG/EML.
Main findings
The WHO has a Model list of essential medicines which
serves as a guide for countries for the development of
their individual country specific EMLs. It is recommended
by the WHO that the process of medicines selection be
based on safety, efficacy, quality, and comparative cost-
effectiveness [17]. Other influencing factors include
pharmaco-economic and health economic assessments,
Quality of Adjusted Life-Years, cost, budget, tenders, price
negotiations, therapeutic classes all affecting medicine
selection. National EMLs should be used to guide
procurement, supply and use of medicines in the
country. Currently there are over 156 countries who
have adopted an EML including SA.
The SA NEMLC is a multidisciplinary, multi-
stakeholder committee with the secretariat and members
from the PTCs as supporting structures. The participants
have stressed the independence and autonomy of the
committee in the medicines selection process although
other guidelines from other local and global organizations
and committees such as those made available for HIV, TB,
and Asthma for example, may be considered but do not
completely influence the decision making process. Partici-
pants have described the process as “transparent” and
“evidence based”. The concept of EBM is rooted in the
medicines selection process and no decision is made
Table 3 Participants’ views on how the NEMLC and its processes have changed over time
Issue Comment
Time period for revision of
EMLs
“So standard treatment guidelines, the last one was published in 2006, for paediatrics for instance, and it’s just been
reviewed. And there’s a recognition that this time period was too long and that it should be shorter and so we hope to
be able to review it in a much shorter time frame in the future. So I think the plan, we’ve already started to, just after the
publication of this one; we started the review of the next one. So the idea is almost yearly or two-yearly and especially
once we move on to an electronic database that the standard treatment guidelines can be updated almost continuously
as things change, evolve”. (2013)
“I would say at this point yearly probably now. With every review of the STG we do it yearly. Prior to this it was
happening every few years you know since 2006. That was more like eight years, but the idea is to increase the
turnaround at the time” (2013)
Changes in selection
criteria
“Prior to, I’d say 2005, we looked predominantly at acquisition price but since 2005 there has been a systematic inclusion
of pharma-economic principles. And currently no medicine is added without at least a consideration of the pharma-
economic”. (1996–2012)
“I seem to recall at that time even though we were more interested in efficacy regardless of the cost therefore we rarely
looking at cost effectiveness analysis. There was a pressure also to consider the cost of a drug, because we wanted to
lend selection to procurement. Although for a long time that hasn’t happened. So we didn’t really do cost minimization
for the time, any kind of consideration at the time, I think things improved over time, for the first few years, I wouldn’t
say we were that strong in our evaluation of the cost effectiveness of medicines”. (1996)
Committee policies and
processes
“Potential conflict of interest in the membership of this committee, we probably didn’t have much in place at the
beginning, but with time I think with experience we realised that something needed to be developed that would be
signed by members, something that can ensure that at the beginning of the year they would declare anything that
would bring them into conflict, but I cannot vouch that we did it from the second year, it might have been years before
that actually happened”. (1996)
“Are other committees consulted? Yes, of late now with the advent of pharmacists that are PTC committees. I think that
is happening”. (PTC, 2003)
I don’t know if it’s called a policy but they do have a SOP in place now to address medicine product shortages. They have a
formulary against which you check to see if the product is on tender etc. but the whole process is unclear”. (PTC, 2003)
How often are committee policies reviewed? “I don’t recall that we had that mechanism in place at the beginning; it
might have been developed later”. (1996)
General comments “The only comment is that this has been an evolving process, we’ve learnt through our own educational process, trial,
error and trying to explore. And that process has been evolving and continues to evolve. But in effect I think it’s been
highly successful and certainly from where we started off with nothing, I think we were able to produce something that
was exceedingly successful and we very grateful that we were able to do that work”. (2003–2012)
“The South African one was developed from nowhere and actually has come quite a long way but I think it is time for it
to be revisited and there are attempts to look at where we are going in the future and perhaps to re-evaluate what we
are doing and why we are doing it, clearly a blessing to a guideline committee and more into a strict formulary thing
which would be easier to measure”. (2003–2012)
“Well for us, I mean, although we had information from others who had experience in their own right, and there have
been attempts previously, by previous health departments to have some kind of formularies or lists, this was really a new
experience and I think it took time before we managed to establish ourselves as department of health and EDL
committees that were sort of well-established and was able to follow international best practices. I think it took
some time before we could get to that, you know, we started by crawling, gradually over time I think things
would have become much better. I recall that we also used to comment at the WHO, we would advise on one
or the other mechanism of doing reviews. It was really quite an experience, new experience for us”. (1996)
“It is a very thorough process, people that are not on NEMLC would think who are these people sitting and making
decisions but it’s a very thorough process and it’s a very transparent process”. (2013)
Perumal-Pillay and Suleman BMC Health Services Research  (2017) 17:17 Page 13 of 17
without first considering the best available evidence. This
is evidence of one of the many changes over the years as
described in Table 2, which is a synopsis of notable quotes
from participants which indicate how the NEMLC pro-
cesses have changed over time.
Comparisons with other studies
The WHO concept of essential medicines has gained
global acceptance. Currently 4 out of 5 countries world-
wide have a national EML, making the WHO Model
EML a cornerstone in essential medicines policies [17].
SA is one of these countries to have effectively adopted
and developed a national EML since 1996, based on
WHO guidelines. The overall structure of the SA STG/
EMLs has remained largely unchanged over the years.
This is consistent with the WHO Model EMLs which
have also maintained their structure but different in that
the WHO Model EML medicine selection process has
matured and has moved from a more experience-based
approach (used before 1999) to a more evidence based
approach (adopted since 2002) [5] whilst the SA EMLs
medicine selection process has always been evidence
based with the process itself becoming more stringent
over the years. Post 2002, the WHO expert committee
refined the medicine selection process to include evidence
for public health relevance, efficacy, and cost-effectiveness.
In addition, guidelines also now include input from vari-
ous stakeholders who sit on the expert committee. These
criteria are all similar with the current process in SA [18].
The process of EML review for SA and the WHO is
very much the same and this is discussed below. Both
processes apply evidence based approaches for medicine
selection using a number of criteria viz. the disease bur-
den, availability of sound and adequate evidence on
safety, efficacy, and comparative cost-effectiveness of
available treatments, although the pharmacoeconomic
aspect still requires some strengthening in SA. Further-
more, where availability of evidence is inadequate The
WHO Expert committee either waits for more evidence
or bases its decision on expert opinion or experience.
The same is true for SA, where value judgements are
made and expert opinions or lower levels of evidence
are considered, such as case reports or consensus opin-
ions. The process of applications for amendments, addi-
tions, deletions of medicines to the WHO Model EML is
submitted via relevant departments to the secretary of
the WHO Expert committee. In SA, this process occurs
through the EDP who receives all motivations for
amendments to the EML. The selection of members
onto the WHO Expert committee is done by the Dir-
ector General from the WHO Expert Advisory Panels
and members are selected based on gender balance, geo-
graphical representation and professional competencies.
All potential conflicts of interest are declared by the
members and captured in the respective Technical re-
port series. The member selection is similar in SA with
the exception of gender balance and the NEMLC is
appointed by the National Minister of Health and there
is also a conflict of interest declaration made by the
members of the NEMLC.
The WHO process differs in that all applications for
amendments must be received four months prior to the
meeting of the Expert committee and all application re-
views/comments are made available on the webpage and
verified for completeness by the secretary of the Expert
committee. The final outcome is summarized and pub-
lished in a WHO Technical Series Report. This process
is very transparent and SA has not adopted this latter
phase of the medicine selection and review process as
yet. The WHO process also allows for patient advocacy
groups to comment on the various applications and draft
recommendations although these are not used in the de-
cision making part of the process. This is also not some-
thing currently considered in SA.
Australia has a Pharmaceutical Benefits Scheme (PBS)
which pays for most prescription medicines. It is one of
many government programs which applies evidence-based
decision making to the funding of health technologies.
PBS processes support the provision of affordable, equit-
able access to prescription medicines and is not a cost
containment tool. Similar to the NEMLC in SA, Australia
has The Pharmaceutical Benefits Advisory Committee
(PBAC) which is an independent statutory committee,
appointed by the Minister of Health, and is responsible for
the selection of medicines onto the national formulary.
PBAC are advisory to the Minister for Health and Ageing
who takes the final decision to list a medicine. The PBAC
process of medicine selection is also evidence based as is
the case in SA. They also take into account both compara-
tive effectiveness and comparative cost-effectiveness of
medicines during selection [19].
Botswana developed its National drug policy in 1999.
The first Botswana EML was published in 2005 and re-
vised in 2012. The lag in revision is similar to the first
set of SA EMLs. The committee responsible for medi-
cine selection is the National Standing Committee on
Drugs. The Botswana EML was adapted from the WHO
Model EML (April 2003 version). Criteria for medicine
selection was based on WHO guidelines. The National
Standing Committee on Drugs engaged in a consultation
process with Drugs and Therapeutics committees at dif-
ferent levels of health facilities during development of
the EML whereby a draft of the EML was circulated for
comment [20]. The central medical stores is responsible
for procurement of medicines and medical supplies for
the public sector. There is also a monitoring component
of the EML process whereby the central medical stores
collects usage and consumption data on quantities of
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medicines received and distributed and the cost of these
medicines via a computerized system [21].
From the above discussion on some country specific
EML processes it is evident that SA’s EML process aligns
well with the WHO process.
The successful implementation of a medicines
programme is the evaluation of the medicines policy and
continuous monitoring of the use of medicines. Know-
ledge of the impact of the policy is vital for further de-
velopment [22]. Some national medicines policies may
address the importance of M&E, but the actual indica-
tors for monitoring or the framework for monitoring are
often lacking within the policy itself [23]. The challenges
experienced by NEMLC members in the SA EML
programme in terms of communication between depart-
ments and committees, the lack of technical expertise
for health economic analyses, the difficulty with align-
ment of processes, and the poor M&E of policy is not
unique to SA. These are common constraints encoun-
tered by countries employing any national medicines
policy, as explained in a policy and legal framework
document for National medicines policies published by
Management Sciences for Health (2012) [24]. A list of
indicators to assist with monitoring medicines policy has
been developed by the WHO and may be adapted to suit
the needs of specific countries as every country’s medi-
cines policy is unique to their situation and need [25].
It is explained that there are many actors involved in
the efficient running of a medicines policy, from the na-
tional government departments of health, trade and in-
dustry, and finance, to health professionals, academics,
public and private wholesalers, retailers and local and
international pharmaceutical manufacturers, provincial
and district health departments, and NGOs. This diverse
group of participants makes the efficient running of a
medicines programme multi-faceted and difficult. An ef-
ficient system to monitor and evaluate a medicines pol-
icy must be in place as it serves as a management tool
for the assessment of progress of the policy. It assists
policy makers to make appropriate management deci-
sions to respond to identified problems with the policy
and engage in discussions with national stakeholders to
problem-solve and improve the performance of the
programme. A strong partnership from all actors in-
volved is required for a successful medicines policy
process [24].
A study conducted by Roughead et al., 2016 [22] de-
scribes a few countries experiences with monitoring sys-
tems for the use of medicines and may serve as
examples that SA can use to strengthen its M&E aspect
of the medicines policy. These are summarized below.
Bhutan has an essential medicines and technology div-
ision which provides systematic, evidence based infor-
mation to the Ministry of Health. Progress of the policy
is evaluated using a subset of the WHO indicators for
monitoring medicine policy together with DURs. Monitor-
ing involves analysing if medicines belonged to the NEML
and the number of medicines on each prescription.
Indonesia has a rational use of medicines programme
that monitors medicine use at all health facilities in the
country. Data is collected, using the WHO indicators,
daily at health centres, monthly at district or municipal of-
fices and sent to the minister biannually for compilation
of the annual national performance indicators report
Malaysia monitors medicine use by using numerous
data sources viz. National Pharmacy Service Statistics,
National Medicines use survey and the National medi-
cines price survey. The data is used to assess utilization,
prescribing patterns, quality of healthcare, pharmaceutical
expenditure, price variations and to monitor and evaluate
the effects of interventions for rational drug use.
The Republic of Korea does not have a formal national
medicines policy but has a system of National health in-
surance. A national e-health platform allows data collec-
tion for medicine monitoring purposes. The country also
has a DUR programme.
Strengths and limitations
We gathered perspectives and opinions from past and
current members of the NEMLC about their experiences
with the committee, its procedures and processes sur-
rounding essential medicines selection over the years.
The sample was representative of the wide spectrum of
members on the committee as members from the
NDoH, provincial DoH, and PTCs participated. In
addition, we were able to recruit NEMLC members from
every committee for every level of the NEMLC from the
very first EML in 1996 to the 2013 committee. The sam-
ple was not geographically representative of all 9 prov-
inces, although the 4 largest provinces were represented,
and valuable opinions from these individuals have not
been captured in the study. The element of recall bias
must be considered for all participants, especially for
those participants who were from the very first NEMLCs
from 20 years ago. Furthermore, the familiarity with
NEMLC processes may have been over-reported as par-
ticipants were provided the opportunity to peruse the
interview questions prior to the interview.
What this study adds and suggestions for future studies
This research has highlighted the accomplishments of
the NEMLC and the EMP, over the years. The research
has also brought to the fore, the poor monitoring and
evaluation component of the current EML system. Al-
though this is listed as a requirement of the NDP for
SA, 20 years later it still remains fairly unfulfilled. The
authors recommend that this component of the EML
policy be strengthened as it is one of the critical building
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blocks for an efficient, informed, sustainable EML
process and impacts largely on attaining better health-
care for all citizens. Further studies are required to in-
vestigate the actual reporting mechanisms and reporting
committee functions from the ground up at a local and
PPTC level that feeds and supports the M&E compo-
nent, headed by the NEMLC. Studies probing the total
financial consequences of the listing decisions such as
budget impact analysis of adding medicines must be ex-
plored and clarity on how the committee establishes a
medicine to be “affordable” must also be further investi-
gated. These studies will contribute to a better under-
standing of how decisions are made taking the country’s
budget into account. SA can capitalize on the experi-
ences from other countries such as Australia, Norway,
Canada and Italy where budget impact assessment is a
formal requirement in the reimbursement decision mak-
ing process [16].
It is important to note that the development of an
EML is only the starting point of the EDP process; it
must be effectively linked to the processes for procure-
ment, supply, training, and monitoring and evaluation of
prescribing and medicine use for it to make a positive
impact and valuable contribution to better healthcare.
From the discussion above it is evident that indicators
or some kind of performance standard is required to as-
sess the progress of a policy or to assess the effects of
policy decisions that result in changes in the policy. For
this process to be effective major resources including
human resources for data collection and interpretation
are required. Furthermore, budget impact analysis of
committee decisions on medicines selection is lacking
and needs to be expanded upon.
Conclusions
This is the first study in SA to report on how decisions
are taken to include or exclude medicines on SA STG/
EMLs and provides insight into the SA STG/EML medi-
cine selection, review and monitoring processes over time.
There may be opportunities for the SA medicines pol-
icy to be strengthened by taking a leaf from other coun-
tries’ experiences as described above. Further studies are
required to confirm this. However, the lessons learnt
from the SA experience with STG/EMLs and medicine
selection over the last 20 years serves as a noteworthy
example for other low-middle income countries when
developing their own NEMLs or even for the process of
STG/EML review.
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